The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease
Abstract
Interstitial lung disease (ILD) is an increasingly recognized complication of rheumatoid arthritis (RA) and is associated with significant morbidity and mortality. In addition, approximately one‐third of patients have subclinical disease with varying degrees of functional impairment. Although risk factors for RA‐related ILD are well established (e.g., older age, male sex, ever smoking, and seropositivity for rheumatoid factor and anti–cyclic citrullinated peptide), little is known about optimal disease assessment, treatment, and monitoring, particularly in patients with progressive disease. Patients with RA‐related ILD are also at high risk of infection and drug toxicity, which, along with comorbidities, complicates further treatment decision‐making. There are distinct histopathologic patterns of RA‐related ILD with different clinical phenotypes, natural histories, and prognoses. Of these, the usual interstitial pneumonia (UIP) subtype of RA‐related ILD shares a number of clinical and histopathologic features with idiopathic pulmonary fibrosis, the most common and severe of the idiopathic interstitial pneumonias, suggesting the existence of common mechanistic pathways and possibly therapeutic targets. There remain substantial gaps in our knowledge of RA‐related ILD. Concerted multinational efforts by expert centers has the potential to elucidate the basic mechanisms underlying RA‐related UIP and other subtypes of RA‐related ILD and facilitate the development of more efficacious and safer drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Prednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113354 · Cited by 1,621
Klareskog, L., Stolt, P., Lundberg, K., Källberg, H., Bengtsson, C., Grunewald, J., Rönnelid, J., Erlandsson Harris, H., Ulfgren, A., Rantapää‐Dahlqvist, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21575 · Cited by 1,515
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
Self-citationBongartz, T., Nannini, C., Medina‐Velasquez, Y. F., Achenbach, S. J., Crowson, C. S., Ryu, J. H., Vassallo, R., Gabriel, S. E., & Matteson, E. L. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27405 · Cited by 864
Salliot, C., & van der Heijde, D. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.093690 · Cited by 673
Turesson, C., O'Fallon, W. M., Crowson, C. S., Gabriel, S. E., & Matteson, E. L. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.8.722 · Cited by 672
Singh, J. A., Cameron, C., Noorbaloochi, S., Cullis, T., Tucker, M., Christensen, R., Ghogomu, E. T., Coyle, D., Clifford, T., Tugwell, P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61704-9 · Cited by 623
Cited by
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478
Fibrosing interstitial lung diseases: knowns and unknowns
Cottin, V., Wollin, L., Fischer, A., Quaresma, M., Stowasser, S., & Harari, S. (2019) · European Respiratory Review · doi:10.1183/16000617.0100-2018 · Cited by 336
Self-citationKadura, S., & Raghu, G. (2021) · European Respiratory Review · doi:10.1183/16000617.0011-2021 · Cited by 328
Spagnolo, P., Distler, O., Ryerson, C. J., Tzouvelekis, A., Lee, J. S., Bonella, F., Bouros, D., Hoffmann-Vold, A.-M., Crestani, B., & Matteson, E. L. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217230 · Cited by 259
Self-citationSelman, M., & Pardo, A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101393 · Cited by 211
Metadata
- Authors
- Spagnolo, P., Lee, J. S., Sverzellati, N., Rossi, G., & Cottin, V.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2018-09-04
- Volume
- 70
- Issue
- 10
- Pages
- 1544-1554
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2806460375
- Cited by
- 306
- References
- 68
- FWCI
- 16.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease. https://app.cochat.ai/papers/10.1002/art.40574
- The paper
- Spagnolo, P., Lee, J. S., Sverzellati, N., Rossi, G., & Cottin, V. (2018). The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease. Arthritis & Rheumatology. https://doi.org/10.1002/art.40574
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.